Breast cancer is one of the leading causes of cancer-related deaths, and the emergence of resistant tumors has made the existing drugs less effective. The conventional drug discovery process is a time-consuming, expensive, and less accurate process. In this paper, a hybrid Artificial Intelligence, Quantum Computing, and High-Performance Computing framework for the discovery of effective drugs for breast cancer is proposed. The proposed framework for drug discovery involves the application of AI for ligand screening, Quantum Approximate Optimization Algorithm for ligand selection, and the application of both GPU and Quantum Computing for molecular docking and energy optimization, respectively. The proposed hybrid framework for drug discovery reduces the search space from 442 ligands to just 10 ligands, thereby significantly reducing the computational cost of the conventional method. The proposed method of ligand docking using GPUs results in a speedup of over 2 times compared to CPU, and the optimized ligand results in a binding energy of up to -12.92 kcal/mol with the Estrogen Receptor Alpha protein target.
Breast cancer is one of the leading causes of cancer-related deaths, and the emergence of resistant tumors has made the existing drugs less effective. The conventional drug discovery process is a time-consuming, expensive, and less accurate process. In this paper, a hybrid Artificial Intelligence, Quantum Computing, and High-Performance Computing framework for the discovery of effective drugs for breast cancer is proposed. The proposed framework for drug discovery involves the application of AI for ligand screening, Quantum Approximate Optimization Algorithm for ligand selection, and the application of both GPU and Quantum Computing for molecular docking and energy optimization, respectively. The proposed hybrid framework for drug discovery reduces the search space from 442 ligands to just 10 ligands, thereby significantly reducing the computational cost of the conventional method. The proposed method of ligand docking using GPUs results in a speedup of over 2 times compared to CPU, and the optimized ligand results in a binding energy of up to -12.92 kcal/mol with the Estrogen Receptor Alpha protein target.
Background: Breast cancer diagnostic data is complex and accompanied by noise. Quantum machine learning can enhance the accuracy, efficiency, and scalability of artificial intelligence algorithms and has applications in various fields such as drug discovery and personalized medicine. Methods: In the systematic review conducted, the databases PubMed, Embase, Scopus, and Web of Science were searched in December 2024. The search strategy included the keywords "Breast Cancer," "Artificial Intelligence," and "Quantum machine learning" along with their synonyms in article titles. Descriptive, qualitative, review, and non-English studies were excluded. The qualitative evaluation of the articles and the assessment of their bias were determined based on the Joanna Briggs Institute (JBI) indicators checklist. Results: Twenty-nine studies utilizing artificial intelligence models for personalized breast cancer management were selected. Seventeen studies employing various deep learning methods achieved satisfactory results in predicting treatment response and prognosis, effectively contributing to the personalized management of breast cancer. Twenty-six studies demonstrated that machine learning methods could enhance the processes of classification, screening, diagnosis, and prognosis of breast cancer. The methods most frequently used in modeling were quantum support vector machine (QSVM), quantum convolutional neural network (QCNN), and quantum neural network (QNN), with an average AUC of 0.91. Additionally, the average accuracy, sensitivity, specificity, and precision indices of the models ranged from 90% to 96%. Conclusion: Quantum computing can address some challenges arising from the increasing complexity and size of artificial intelligence models. Overall, the combination of artificial intelligence and quantum computing can significantly accelerate the drug discovery process and the development of effective drugs.
The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.
Drug discovery techniques are costly, timely, and complex. Modern high-performance computing (HPC) accelerators are required to overcome the resulting computational challenges of large-scale drug discovery. Current classical accelerators are presented with a trade-off between low latency and high accuracy. Integrating quantum processing units (QPUs) into classical architecture can overcome these limitations, solving complex problems at an accelerated rate while maintaining competitive accuracy, with minor trade-offs observed in some applications. As the full quantum advantage is yet to be achieved, hybrid classical-quantum accelerators are the optimal solution. We propose a hybrid CPU-GPU-QPU (HCGQ) accelerator that is based on an input size threshold, where the CPU assigns smaller input size workloads to the GPU, and larger input size workloads to the QPU. This dynamic workload allocation is realized through software-level integration. It was observed that the HCGQ accelerator achieved up to ten times lower latency for large-scale problems compared to GPU only execution, reducing overall energy consumption.
Abstract High-performance computing (HPC) and quantum computing are increasingly being applied to accelerate the modeling of complex diseases such as cancer. This paper presents a detailed survey of the past five years of research on the independent contributions of HPC and quantum computing to cancer disease modeling, examines efforts to integrate these technologies, and proposes a novel hybrid approach. HPC has enabled large-scale, high-resolution cancer simulations (e.g., cm-scale tumor growth models and patient-specific “digital twin” ensembles) with significant speedups using GPU acceleration and distributed computing. Quantum computing, while still nascent, has shown promise in drug discovery, for example, generating novel KRAS inhibitor molecules, and in improving predictive modeling with quantum machine learning (achieving up to ~ 14% higher AUROC in mortality prediction for colorectal cancer). We compiled a literature survey table summarizing key studies, including their computational approaches (from MPI-based finite element simulations to variational quantum algorithms) and quantitative outcomes (speedups, accuracy gains, scalability limits). Four figures contrast classical HPC and quantum hardware architectures, performance scaling (GPU clusters vs. quantum processors), a hybrid HPC-quantum workflow, and the projected performance gains of our proposed integrated approach. From the synthesis of literature, we hypothesize that integrating real-time quantum solvers as accelerators for HPC cancer simulations, for example, using a quantum linear system solver as a preconditioner in an MPI-parallel tumor growth model, can reduce overall simulation time by ≥ 30% while maintaining sub-1% error margins. We support this hypothesis with back-of-the-envelope performance modeling and aggregated benchmark data. An experimental design is outlined to validate the hypothesis, involving coupling a quantum computing module with an existing HPC cancer simulator and measuring speedup, accuracy, and scalability on representative tumor modeling problems. This work aims to provide a comprehensive perspective on how HPC and quantum computing, separately and together, can push the frontiers of cancer modeling for improved understanding and treatment optimization.
By facilitating quicker and more precise analysis of intricate biological data, the union of quantum computing and Artificial Intelligence (AI) may transform genomic medicine and drug discovery altogether. The study suggests a model for artificial intelligence with quantum-enhanced acceleration based on hybrid quantum-classical models in order to speed up drug discovery and customize therapies. It utilizes deep learning models and Quantum Machine Learning (QML) techniques to analyze patient-specific data, protein structures, and genetic sequences. Large genomic and clinical data sets are processed by conventional deep learning models, while the quantum component carries out efficient data encoding and optimization processes. As compared to other traditional AI-based approaches, the proposed model performs a 30% improved drug target identification when evaluated against more than 1,000 genetic sequences and related clinical outcomes. The hybrid model was as accurate as 98.4% in its prediction and was more accurate than the conventional AI techniques including random forests (accuracy: 91.3%) and gradient boosting machines (accuracy: 93.7%). The methodology also produced an F1-score of 0.95 with accuracy and recall scores of 96.1% and 94.7%, respectively. These results demonstrate how quantum-enhanced AI can reduce the time for computation and improve the accuracy of genomic data analysis, driving significant progress toward personalized therapy and drug development.
Quantum computing is poised to revolutionize pharmaceutical research through its integration with artificial intelligence for drug discovery applications. This article examines how quantum computational approaches address fundamental limitations in traditional drug development pipelines, particularly in molecular modeling and simulation, where classical computing faces exponential scaling challenges. By leveraging quantum mechanical phenomena like superposition and entanglement, quantum algorithms such as the Variational Quantum Eigen solver and the Quantum Approximate Optimization Algorithm offer unprecedented accuracy for simulating protein-ligand interactions and predicting molecular behavior. Strategic industry partnerships between quantum technology companies and pharmaceutical giants are establishing frameworks to translate theoretical quantum advantages into practical applications. The synergistic relationship between AI's pattern recognition capabilities and quantum computing's physical simulation prowess creates a powerful paradigm for accelerating drug development while reducing costs. Applications extend to personalized medicine, where quantum approaches enable the analysis of complex genomic datasets to optimize treatments for individual genetic profiles. While technical challenges persist, the trajectory toward quantum-enhanced drug discovery is clear, with significant benefits anticipated as quantum hardware capabilities continue to advance.